Clinical Data CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment PharmaTimesStudy expands development of the antibody into hepatocellular carcinomaClinical DataOncologyRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) PharmaTimes Study expands development of the antibody into hepatocellular carcinoma Clinical DataOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: In the face of tariffs, FDA-approved drug manufacturing deals are shifting to EuropeNext: FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes Related Stories Clinical Data Boehringer advances duo for aggressive cancers into phase 3 pharminent June 22, 2026 Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026 Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026
